Ep51: Ted Love

Episode Summary

Executive Summary: Ted Love traces his path from a segregated Alabama childhood to biotech leadership and explains Global Blood Therapeutics’ mission to deliver voxelotor, the first disease-modifying sickle cell therapy in decades. The conversation covers his career arc, the drug’s mechanism and trial results, regulatory progress, commercialization plans, pricing/access challenges, and the company’s commitment to global affordability.

Main Topics: Ted Love’s upbringing and career formation (Priority: 5/5): Love describes growing up as one of eight children in Huntsville, Alabama, in a low-resource, segregated environment that shaped his values, ambition, and interest in medicine and science. Scholarships and elite institutions expanded his horizons and prepared him for leadership. From physician-scientist to biotech executive (Priority: 5/5): He recounts training at Haverford, Yale, and Mass General, initially aiming for clinical practice and academia before moving into biotech after being recruited by respected mentors. His path through Genentech, Theravance, and Onyx taught drug development, company building, and leadership. Voxelotor’s scientific rationale and mechanism (Priority: 5/5): The discussion explains voxelotor as a once-daily oral small molecule that binds hemoglobin to prevent polymerization, stopping red blood cell destruction at the root of sickle cell disease and aiming to modify disease biology rather than just manage symptoms. Clinical evidence and FDA path (Priority: 5/5): Love reviews the HOPE trial in 274 patients, published in NEJM, with meaningful hemoglobin increases and a favorable safety profile. GBT is pursuing a rolling NDA and expects potential FDA approval in the first half of 2020. Endpoints, surrogate markers, and disease impact (Priority: 4/5): The conversation addresses why hemoglobin is both a surrogate and clinically meaningful marker, how upstream correction may affect downstream crises and organ damage, and why preventing silent strokes and cumulative injury in children is a key goal. Commercialization, payer dynamics, and pricing (Priority: 4/5): Love outlines the U.S. payer mix, the high existing cost burden of sickle cell disease, and the need to set a price that reflects both therapeutic value and prevalence-based economics while remaining accessible to patients and payers. Global access and equity (Priority: 4/5): The interview closes on GBT’s responsibility to make voxelotor available beyond wealthy markets, especially in Africa, where sickle cell burden is high and capacity to pay is low. Love says the company is actively building an access strategy.

Key Arguments: Ted Love argues that his upbringing in a disciplined, values-driven family and later exposure to elite institutions helped shape his commitment to patients, integrity, and leadership. He contends that biotech provided a broader, more creative way to help patients than academic medicine could, especially when paired with top-tier colleagues and high standards. Love says voxelotor is fundamentally disease-modifying because it acts at the root cause: preventing hemoglobin polymerization and red cell destruction. He emphasizes that hemoglobin is not merely a surrogate endpoint but a clinically vital marker tied to survival, oxygen delivery, stroke risk, and organ protection. He argues the HOPE data show the expected biological effect: improved hemoglobin and red cell health, with early signals toward fewer vaso-occlusive crises. He maintains that sickle cell already imposes very high annual costs and lost productivity, so a successful therapy could offset substantial medical and societal burdens. He asserts that global access is a core obligation, not an afterthought, and that GBT intends to create pathways for availability in low-income countries as well as the U.S.

Data Points: Estimated U.S. sickle cell population: ~100,000 people - CDC statistic cited in the intro Incidence among Black/African American births: 1 in 365 - CDC statistic cited in the intro Incidence among Hispanic American births: 1 in 16,000 - CDC statistic cited in the intro Sickle cell trait among Black/African American babies: 1 in 13 - CDC statistic cited in the intro HOPE study size: 274 patients - Pivotal voxelotor trial discussed in the interview Hemoglobin increase benchmark: >1 g/dL in a majority of patients - Clinical effect reported for voxelotor in HOPE Baseline hemoglobin: ~8.5 g/dL - Typical starting level described for study participants On-treatment hemoglobin: ~10 g/dL - Approximate level reached after treatment in HOPE Dose discussed for approval: 1,500 mg once daily - Dose GBT is filing with the FDA Hemoglobin binding target for efficacy: ~30% - Company estimate of binding needed to stop disease effectively Hemoglobin binding at filed dose: ~25% - Binding achieved by the dose under FDA review Hemoglobin binding at 1,500 mg: ~24% - Approximate binding level described for the tested dose Age in first sickle cell study population: 12 years and older - Current FDA-submission-enabling trials Future pediatric expansion: Down to 9 months - Planned younger-age development program U.S. payer mix: ~65% government payers - Commercial planning discussion Medicaid share: ~50% - Part of the government-payer mix Medicare through disability: ~15% - Part of the government-payer mix Private payers: ~25% - Estimated payer segment Average annual cost of sickle cell care: ~$280,000 per year - Value argument made in pricing discussion Estimated lost lifetime income per patient: ~$700,000 - Societal cost framing used by Love Possible analyst price range mentioned: $40,000–$120,000 per patient - Wedbush estimate referenced by the host Years at Genentech: A little over 6 years - Career chronology Age when joining biotech: About 32–34 - Approximate age when Love moved from academia to industry

Pivotal Quotes: "“this is the best time ever in the treatment of sickle cell, hands down.”" — Luke Timmerman: Opening framing of the episode and why the interview matters now "“if you take it orally once a day, the red cell stops dying.”" — Ted Love: Core summary of voxelotor’s disease-modifying mechanism "“We’re already spending a lot of money and we’re getting terrible outcomes.”" — Ted Love: Argument for why a high-value therapy could justify its cost

Implications: If voxelotor succeeds commercially and clinically, it could become a landmark sickle cell therapy, shift treatment toward earlier disease modification, and create a model for balancing value-based pricing with global access in underserved populations.